USA-based PixarBio Corp (OTCQX: PXRB) announced on Friday that, under a January 23, 2017 Order, trading of its securities were temporarily suspended by the Securities and Exchange Commission. The suspension is scheduled to last from January 23, 2017 through February 3, 2017 at 11:59 pm.
According to the SEC, "the market for the security appears to reflect manipulative or deceptive activities."
PixarBio is currently in the process of providing the SEC with documentation. Just last week, the company announced that it was withdrawing its unsolicited offer to acquire InVivo Therapeutics (Nasdaq: NVIV).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze